In addition to the MRD oral abstract, additional research highlights include: “We have an exciting, diverse, and sizable slate of oncology results being presented at ASCO this year, where each ...

The Company previously reported exploratory biomarker data from the SER-155 Phase 1b study showing evidence of improved intestinal epithelial barrier integrity and modulation of systemic inflammatory ...